For years, researchers have suspected that inflammation plays a role in depression. Now, a new study suggests that targeting the immune system might help treat a specific subtype of depression—one that's often resistant to conventional antidepressants.

The research, published in the journal PsyPost, found that when patients are selected based on elevated inflammation markers, certain immune-modulating drugs reduce not only general depressive symptoms but also anhedonia—the inability to feel pleasure that's one of depression's most debilitating features.

This is precision medicine applied to psychiatry. Instead of the current trial-and-error approach to antidepressants (try this one for six weeks, if it doesn't work try another), the research suggests we might be able to identify which patients will respond to immune-targeted treatments by measuring biological markers.

The inflammation-depression connection has been building in the scientific literature for over a decade. People with depression often show elevated levels of inflammatory markers like C-reactive protein, interleukin-6, and tumor necrosis factor-alpha. Depression rates are higher in people with inflammatory conditions like rheumatoid arthritis and inflammatory bowel disease. And some studies have shown that anti-inflammatory medications can have mood-improving effects.

But the relationship is complex. Not everyone with depression has elevated inflammation, and not everyone with inflammation has depression. The key insight from this latest research is that if you select patients with both depression and elevated inflammation markers, immune-targeted drugs appear to work.

Anhedonia—the loss of pleasure in activities that used to bring joy—is particularly resistant to treatment. Many antidepressants can improve mood and reduce negative symptoms like sadness or anxiety, but they're less effective at restoring the capacity for positive emotions. The fact that immune-targeted drugs showed effects on anhedonia specifically is notable.

The study doesn't specify exactly which drugs were tested, but the class of medications likely includes things like NSAIDs (non-steroidal anti-inflammatory drugs), TNF inhibitors used for autoimmune conditions, or newer anti-inflammatory agents. Each has different mechanisms, side effect profiles, and practical considerations.

Now, the important caveats. Depression is not simply "brain inflammation." The biology of depression involves neurotransmitters, neuroplasticity, stress hormones, genetics, sleep, and a dozen other factors. Inflammation appears to be in with depression.